Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209116 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19628622 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12466620 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL799468 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4203114 | 1.00 | FFAR1 (0.81) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12646402 | 0.94 | FFAR1 (0.73) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1550383 | 0.90 | FFAR1 (1.00) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21845792 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL799523 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16232159 | 0.84 | ALDH1A1 (0.64) | FFAR1ALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-1996560-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104717-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NEUROSEARCH A/S (DK) | 2007-09-20 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | TEIJIN PHARMA LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-7790758-B2 | glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives | GLAXO GROUP LIMITED (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1996560-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| WO-2007104717-A1 | QUINAZOLINONES AND THEIR USE AS POTASSIUM CHANNELS ACTIVATORS | NEUROSEARCH A/S (DK) | 2007-09-20 | — | — | WO | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036473-A1 | NOVEL QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNK17, KCNN3, KCNA7 | FFAR1 2816/4885ALDH1A1 2372/4885CYP1A2 999/4885 |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | FFAR1 4727/4885ALDH1A1 3259/4885CYP1A2 724/4885 |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | FFAR1 4743/4885ALDH1A1 2036/4885CYP1A2 1179/4885 |
| US-20110313169-A1 | PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST | XDH, PAH, HPRT1 | FFAR1 1548/4885ALDH1A1 308/4885CYP1A2 38/4885 |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | FFAR1 91/4885ALDH1A1 1604/4885CYP1A2 2732/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | FFAR1 4637/4885ALDH1A1 2100/4885CYP1A2 906/4885 |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | FFAR1 58/4885ALDH1A1 1698/4885CYP1A2 256/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | FFAR1 4334/4885ALDH1A1 734/4885CYP1A2 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.